A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

References

• Miller JS, Oelkers S, Verfaillie C, McGlave P. Role of monocytes in the expansion of human activated natural killer cells. Blood. 1992;80:2221–9.
   PubMed Web of Science ®Google Scholar
• Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR− primitive progenitors in long-term bone marrow culture. Blood. 1992;80:2182–7.
   PubMed Web of Science ®Google Scholar
• Pierson B, Miller J, Verfaillie B, McGlave P, Hu W-S. Population dynamics of human activated killer cells in culture. Biotech Bioeng. 1994;43:685–92.
   PubMed Web of Science ®Google Scholar
• Miller JS, Alley KA, McGlave P. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood. 1994;83:2594–601.
   PubMed Web of Science ®Google Scholar
• Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant. 1994;14:555–62.
   PubMed Web of Science ®Google Scholar
• Pierson BA, McGlave PB, Hu WS, Miller JS. Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. J Hematother. 1995;4:149–58.
   PubMedGoogle Scholar
• Pierson BA, Gupta K, Hu WS, Miller JS. Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors. Blood. 1996;87:180–9.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996;87:2476–85.
   PubMed Web of Science ®Google Scholar
• Pierson BA, Europa AF, Hu WS, Miller JS. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor. J Hematother. 1996;5:475–83.
   PubMedGoogle Scholar
• Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood. 1996;88:2279–87.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell. 1995;82:697–700.
   PubMed Web of Science ®Google Scholar
• Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995;267:978–9.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Karnofsky Memorial lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10: 180–99.
   PubMed Web of Science ®Google Scholar
• Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, . Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463–9.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889–97.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Bjorkstrom NK, Norell H, Bryceson Y, van Hall T, Baumann BC, . DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 2007;67:1317–25.
   PubMed Web of Science ®Google Scholar
• Cooley S, Burns L, Repka T, Miller J. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol. 1999;27: 1533–41.
   PubMed Web of Science ®Google Scholar
• Lotzova E, Savary CA, Freedman RS, Bowen JM. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol Immunother. 1984;17:124–9.
   PubMed Web of Science ®Google Scholar
• Lotzova E, Savary CA, Freedman RS, Edwards CL, Wharton JT. Recombinant IL-2-activated NK cells mediate LAK activity against ovarian cancer. Int J Cancer. 1988;42:225–31.
   PubMed Web of Science ®Google Scholar
• Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 1996;2:161–73.
   PubMed Web of Science ®Google Scholar
• Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, . P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med. 1993;178: 597–604.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, . Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26: 5233–9.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, . Increased intensity lymphodepletion and adoptive immunotherapy: how far can we go? Nat Clin Pract Oncol. 2006;3:668–81.
   PubMedGoogle Scholar
• Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, . Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 2008;181:3291–300.
   PubMed Web of Science ®Google Scholar
• Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun G, Fautsch S, . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–7.
   PubMed Web of Science ®Google Scholar
• Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol. 2005;17:195–201.
   PubMed Web of Science ®Google Scholar
• McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, . Good manufacturing practice production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47: 520–8.
   PubMedGoogle Scholar
• Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, . Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant. 1997;3: 34–44.
   PubMedGoogle Scholar
• Cooley S, Gada P, McKenna D, McCullar V, Fautsch S, Verneris M, Blazar BR, . Successful haploidentical hematopoietic cell engraftment using a non-myeloablative preparative regimen including natural killer (NK) cells. Blood. 2008;112:Abstract 827.
   Google Scholar
• Thyagarajan B, Young S, Floodman S, Peterson R, Wang X. Systematic analysis of interference due to stutter in estimating chimerism following hematopoietic cell transplantation. J Clin Lab Anal. 2009;23:308–13.
   Google Scholar
• Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92: 205–16.
   PubMed Web of Science ®Google Scholar
• Reed M, Yearsley M, Krugh D, Kennedy MS. Severe hemolysis due to passenger lymphocyte syndrome after hematopoietic stem cell transplantation from an HLA-matched related donor. Arch Pathol Lab Med. 2003;127:1366–8.
   Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233–40.
   PubMed Web of Science ®Google Scholar
• Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, . Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10:625–32.
   PubMed Web of Science ®Google Scholar
• Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13: 5243–8.
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Cianci R, Lolli S, Dunn IS, Newton EE, Haggerty TJ, . Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol. 2008;21:493–500.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211–8.
   PubMed Web of Science ®Google Scholar
• Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200:771–82.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, . Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766–72.
   PubMed Web of Science ®Google Scholar
• Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, . Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA. 2005;102:419–24.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, . Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18–32.
   PubMed Web of Science ®Google Scholar
• Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28:120–8.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, . Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;114:3793–802.
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Dummer W, Kono DH. T cell homeostasis and systemic autoimmunity. J Clin Invest. 2001;108:335–40.
   PubMed Web of Science ®Google Scholar
• Maine GN, Mule JJ. Making room for T cells. J Clin Invest. 2002;110:157–9.
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, de Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–8.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018–25.
   PubMed Web of Science ®Google Scholar
• Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R, . Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:382–8.
   PubMed Web of Science ®Google Scholar
• Bocian K, Borysowski J, Wierzbicki P, Wyzgal J, Klosowska D, Bialoszewska A, . Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol Dial Transplant. 2009;25:710–7.
   Google Scholar
• Yokoyama H, Lundqvist A, Berg M, Ramanathan M, Lopez R, Smith A, Gormley N, . Adoptively infused NK cells maintain their antitumor effects in vivo in the presence of cyclosporin A (CSA). Blood. 2008;112;Abstract 2563.
   Google Scholar
• Chan JK, Lin SS, McMeekin DS, Berman ML. Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer. J Clin Oncol. 2005;23:6794–5.
   PubMedGoogle Scholar
• Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol. 1993;21:521–4.
   Google Scholar
• Yahata T, Nishikawa N, Aoki Y, Tanaka K. Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer. Gynecol Oncol. 2006;103:752–4.
   PubMed Web of Science ®Google Scholar
• Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol. 1994;17:502–5.
   Google Scholar